Morgan Stanley Logic Bio Therapeutics, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.29 - $0.67 $0 - $0	-1 Reduced 0.01%	10,725 $3,000
Q2 2022 Oct 27, 2022	SELL	$0.35 - $0.74 $492 - $1,041	-1,407 Reduced 11.6%	10,726 $4,000
Q2 2022 Aug 15, 2022	SELL	$0.35 - $0.74 $492 - $1,041	-1,407 Reduced 11.6%	10,726 $4,000
Q1 2022 Oct 27, 2022	BUY	$0.61 - $2.49 $858 - $3,503	1,407 Added 13.12%	12,133 $8,000
Q1 2022 May 13, 2022	SELL	$0.61 - $2.49 $1,082 - $4,417	-1,774 Reduced 12.76%	12,133 $8,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.53 $7,073 - $14,563	3,215 Added 30.07%	13,907 $32,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $5.09 $41,164 - $54,422	10,692 New	10,692 $49,000

Ticker LOGC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,962,700
Description
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.